• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEWLLM Arena
    Legal
    Terms of usePrivacy policyCookie policy

    OSR Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    10/16/25 11:10:18 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care
    Get the next $OSRH alert in real time by email
    false 0001840425 0001840425 2025-10-13 2025-10-13 0001840425 OSRH:CommonStockParValue0.0001PerShareMember 2025-10-13 2025-10-13 0001840425 OSRH:RedeemableWarrantsExercisableForSharesOfCommonStockAtExercisePriceOf11.50PerShareMember 2025-10-13 2025-10-13 iso4217:USD xbrli:shares iso4217:USD xbrli:shares

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    FORM 8-K

     

    CURRENT REPORT

     

    Pursuant to Section 13 OR 15(d) of The Securities Exchange Act of 1934

     

    Date of Report (Date of earliest event reported): October 13, 2025

     

    OSR HOLDINGS, INC.

    (Exact Name of Registrant as Specified in Charter)

     

    Delaware   001-41390   84-5052822
    (State or Other Jurisdiction   (Commission File Number)   (IRS Employer
    of Incorporation)       Identification No.)

     

    10900 NE 4th Street, Suite 2300, Bellevue, WA   98004
    (Address of Principal Executive Offices)   (Zip Code)

     

    Registrant’s telephone number, including area code (425) 635-7700

     

    Not Applicable
    (Former Name or Former Address, if Changed Since Last Report)

     

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

     

    ☐ Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
       
    ☐ Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
       
    ☐ Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
       
    ☐ Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e 4(c))

     

    Securities registered pursuant to Section 12(b) of the Act:

     

    Title of each class   Trading Symbol(s)   Name of each exchange on which registered
    Common stock, par value $0.0001 per share   OSRH   The Nasdaq Stock Market LLC
    Redeemable warrants, exercisable for shares of common stock at an exercise price of $11.50 per share   OSRHW   The Nasdaq Stock Market LLC

     

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

     

    Emerging growth company ☒

     

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     

     

     

     

     

    Item 1.01. Entry into a Material Definitive Agreement.

     

    On October 13, 2025, OSR Holdings Co., Ltd. (“OSRK”), a wholly owned subsidiary of OSR Holdings Inc. (NASDAQ: OSRH, the “Company”), entered into a Share Exchange Agreement (the “Agreement”) with Woori IO Co., Ltd. (“WORIO”). Under the Agreement, OSRK will acquire all issued and outstanding shares of WORIO through a comprehensive share exchange under the Korean Commercial Act, and WORIO will become a wholly owned subsidiary of OSRK and indirectly of the Company.

     

    WORIO is a South Korea-based medical-device company developing non-invasive biosensing technology for glucose monitoring and related health parameters. Its proprietary near-infrared spectroscopy (NIRS) platform aims to enable needle-free continuous glucose monitoring for diabetes patients. Of particular note, WORIO has been providing technical development services to Samsung Electronics (“Samsung”) under a Non-invasive Blood Glucose Monitor PoC Development Services Agreement(“Service Agreement”) pursuant to which Samsung provided WORIO with a certain amount of non-dilutive funding. The details of such funding will not be disclosed in order to protect Samsung’s business confidentiality. This Service Agreement serves as the basis for WORIO to conduct the trials to test the Proof of Concept of WORIO’s NIRS technologies in monitoring and collecting data on blood glucose levels of the patients who participated in the trials. These programs, conducted under the Service Agreement, provide collaborative support for product validation and pilot testing of WORIO’s non-invasive glucose monitoring devices.

     

    Each WORIO share will be exchanged for 0.948832 OSRK shares, and OSRK will issue 84,338 new shares in total to the existing WORIO shareholders in exchange for their 88,891 WORIO shares. The aggregate transaction value is approximately KRW 15 billion (USD 10.6 million).

     

    The closing of the transaction is subject to customary conditions including shareholder approval by WORIO (target meeting date December 19, 2025) and regulatory clearances. The effective date of the share exchange is expected to be January 12, 2026.

     

    Under Annex 2 of the Agreement, if within three years after closing the Company’s common stock reaches USD 10.00 per share on NASDAQ, the OSRK shares received by former WORIO shareholders may be exchanged for OSR Holdings Inc. common stock at a ratio of 12.96 OSRH shares for each OSRK share, subject to applicable U.S. securities laws and Board approval. A copy of Annex 2 of the Agreement is filed as Exhibit 2.1A and incorporated herein by reference.

     

    Item 7.01. Regulation FD Disclosure

     

    On October 14, 2025, the Company issued a press release announcing the execution of the definitive agreement to acquire Woori IO Co., Ltd. A copy of the press release is furnished as Exhibit 99.1 to this Current Report on Form 8-K.

     

    1

     

     

    Item 9.01. Financial Statements and Exhibits

     

    (d) Exhibits

     

    EXHIBIT INDEX

     

    Exhibit No.   Description
    2.1A   Annex 2 (Conditions for Exchange into OSR Holdings Inc. Shares), excerpted from the Share Exchange Agreement dated October 13, 2025, by and among OSR Holdings Co., Ltd. and Woori IO Co., Ltd. (only Annex 2 included; all other portions omitted pursuant to Item 601(b)(2) of Regulation S-K)
    99.1   Press Release dated October 14, 2025 titled “OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care.”
    104   Cover Page Interactive Data File (embedded within the Inline XBRL document)

     

    Certain portions of the Share Exchange Agreement relating solely to OSR Holdings Co., Ltd. and Woori IO Co., Ltd. have been omitted as they are not material to OSR Holdings Inc. and would likely cause competitive harm if disclosed. OSR Holdings Inc. agrees to furnish supplementally a copy of any omitted portions to the Securities and Exchange Commission upon request.

     

    2

     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

    Dated: October 16, 2025

     

      OSR HOLDINGS, INC.
           
      By: /s/ Kuk Hyoun Hwang
        Name:  Kuk Hyoun Hwang
        Title: Chief Executive Officer

     

    3

     

    Get the next $OSRH alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $OSRH

    DatePrice TargetRatingAnalyst
    More analyst ratings

    $OSRH
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    OSR Holdings Signs Definitive Agreement to Acquire Woori IO, a Pioneer in Noninvasive Glucose Monitoring with Potential to Transform Diabetes Care

    BELLEVUE, Wash., Oct. 14, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH) today announced that it has executed a definitive agreement to acquire Woori IO Co., Ltd. ("WORIO"), a pioneer in noninvasive glucose monitoring (NIGM), via a comprehensive share exchange. The acquisition reinforces OSRH's dedication to advancing biomedical innovation by adding a potential breakthrough technology for diabetes care, bringing truly needle-free glucose monitoring closer to patients globally and promising a safer, more convenient and accurate alternative to currently available technologies.

    10/14/25 8:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Receives Nasdaq Minimum Bid Price Deficiency Notice; Company Highlights Unusual Trading Activity

    BELLEVUE, Wash., Sept. 9, 2025 /PRNewswire/ -- OSR Holdings (NASDAQ:OSRH) today announced that on September 5, 2025, it received a written notification from The Nasdaq Stock Market LLC ("Nasdaq") stating that the Company is not in compliance with Nasdaq Listing Rule 5550(a)(2), which requires listed securities to maintain a minimum bid price of $1.00 per share. The notice does not affect the listing of OSR Holdings' common stock, which will continue to trade on the Nasdaq Capital Market under the ticker symbol "OSRH." In accordance with Nasdaq rules, the Company has until Marc

    9/9/25 5:30:00 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings to Host Virtual Investor Event Providing Key Corporate Updates and Strategic Direction on August 6, 2025

    BELLEVUE, Wash., Aug. 1, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a  global healthcare company advancing biomedical innovations to improve health and wellness worldwide, today announced that it will host a Virtual Investor Event on Wednesday, August 6, 2025 at 8:00 a.m. Eastern Time (2:00 p.m. Central European Summer Time / 9:00 p.m. Korea Standard Time). The event will provide shareholders and prospective investors with a detailed update of the Company's strategic direction, subsidiary performance, capital allocation, and pipeline R&D. Senior members of the OSRH

    8/1/25 1:29:00 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    View All

    SEC Form 3 filed by new insider Fierz Reto Kaspar

    3 - OSR Holdings, Inc. (0001840425) (Issuer)

    10/24/25 12:58:23 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    SEC Filings

    View All

    OSR Holdings Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Regulation FD Disclosure, Financial Statements and Exhibits

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    10/16/25 11:10:18 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    SEC Form 8-K filed by OSR Holdings Inc.

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    9/23/25 8:40:55 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Inc. filed SEC Form 8-K: Notice of Delisting or Failure to Satisfy a Continued Listing Rule or Standard; Transfer of Listing

    8-K - OSR Holdings, Inc. (0001840425) (Filer)

    9/9/25 4:47:39 PM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    $OSRH
    Leadership Updates

    Live Leadership Updates

    View All

    OSR Holdings Appoints Dr. Andreas Niethammer as Chief Medical Officer of Vaximm AG, an OSR Company

    BASEL, Switzerland and SEOUL, South Korea, July 15, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr Andreas Niethammer, M.D., Ph.D., as Chief Medical Officer of Vaximm AG, an OSR Company developing a platform of orally administered target-specific T-cell activators, including VXM01, a clinical stage anti-VEGFR-2. . Dr. Niethammer is an internationally recognized oncology expert with over two decades

    7/15/25 7:30:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care

    OSR Holdings Appoints Dr. Constance Höfer as Chief Scientific Officer

    BASEL, Switzerland, March 25, 2025 /PRNewswire/ -- OSR Holdings, Inc. (NASDAQ:OSRH), a global healthcare company dedicated to advancing healthcare outcomes and improving the quality of life for people and their families, today announced the appointment of Dr. Constance Höfer as its new Chief Scientific Officer (CSO). Dr. Höfer, a seasoned leader in drug development with over 20 years of experience in oncology and immunology, will oversee OSR Holdings' scientific strategy and innovation pipeline. Dr. Höfer joins OSR Holdings from Merck Healthcare, where she led global programs spanning from preclinical to late-stage clinical development. Prior to Merck, she held senior leadership positions a

    3/25/25 7:00:00 AM ET
    $OSRH
    Medical/Dental Instruments
    Health Care